Cargando…

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer

Aromatase inhibitors (AI) are drugs that are widely used in treating estrogen receptor (ER)–positive breast cancer patients. Drug resistance is a major obstacle to aromatase inhibition therapy. There are diverse reasons behind acquired AI resistance. This study aims at identifying the plausible caus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadasivam, Kirithika, Manoharan, Jeevitha Priya, Palanisamy, Hema, Vidyalakshmi, Subramanian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korea Genome Organization 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326531/ https://www.ncbi.nlm.nih.gov/pubmed/37415453 http://dx.doi.org/10.5808/gi.23012

Ejemplares similares

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
por: Hayashi, Takanori, et al.
Publicado: (2018)

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer
por: Hoppe, Reiner, et al.
Publicado: (2016)

Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells
por: Augimeri, Giuseppina, et al.
Publicado: (2020)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
por: Nabholtz, Jean-Marc A
Publicado: (2008)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Update on the use of aromatase inhibitors in early-stage breast cancer
por: Kesisis, Georgios, et al.
Publicado: (2009)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
por: Kwan, Marilyn L., et al.
Publicado: (2014)

Network-guided prediction of aromatase inhibitor response in breast cancer
por: Ruffalo, Matthew, et al.
Publicado: (2019)

Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors
por: Qi, Qing-ling, et al.
Publicado: (2022)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer
por: Kazi, Armina A, et al.
Publicado: (2014)

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
por: Lui, Asona, et al.
Publicado: (2016)

Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages
por: Gelsomino, Luca, et al.
Publicado: (2020)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019)

Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
por: Nunes, Frederico Arthur Pereira, et al.
Publicado: (2021)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Potential use of COX-2–aromatase inhibitor combinations in breast cancer
por: Bundred, N J, et al.
Publicado: (2005)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
por: Lønning, P. E.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3lk1jspj0lp9hurcapvmq7b81o